Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2017-04-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/21645515.2017.1296994PMID 28277821PMCID PMC5512770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Searching for the Ideal

  2017cited by this paper
• Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants

  2016cited by this paper
• Recombinant receptor-binding domains of multiple MERS-coronaviruses induce cross-neutralizing antibodies against divergent human and camel MERS-coronaviruses and antibody-escape mutants

  2016cited by this paper
• A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

  2016cited by this paper
• A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.

  2016cited by this paper
• Outbreaks of Middle East Respiratory Syndrome in Two Hospitals Initiated by a Single Patient in Daejeon, South Korea

  2016cited by this paper
• Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines

  2016cited by this paper
• An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

  2016cited by this paper
• Recent Advances of Vaccine Adjuvants for Infectious Diseases

  2015cited by this paper
• Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease

  2015cited by this paper
• Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

  2015influential reference
• Receptor Usage and Cell Entry of Porcine Epidemic Diarrhea Coronavirus

  2015cited by this paper
• Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

  2015influential reference
• Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults

  2015cited by this paper
• Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults.

  2015cited by this paper
• Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus

  2015cited by this paper
• Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies

  2014cited by this paper
• Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections, Tunisia, 2013

  2014cited by this paper
• Current advancements and potential strategies in the development of MERS-CoV vaccines

  2014cited by this paper
• Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness

  2014cited by this paper
• Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus

  2014cited by this paper
• Detection of the Middle East Respiratory Syndrome Coronavirus Genome in an Air Sample Originating from a Camel Barn Owned by an Infected Patient

  2014cited by this paper
• Middle East Respiratory Syndrome Coronavirus Quasispecies That Include Homologues of Human Isolates Revealed through Whole-Genome Analysis and Virus Cultured from Dromedary Camels in Saudi Arabia

  2014cited by this paper
• Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

  2014cited by this paper
• Evidence for camel-to-human transmission of MERS coronavirus.

  2014cited by this paper
• Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

  2014cited by this paper
• Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human Receptor CD26

  2014cited by this paper
• Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design

  2014cited by this paper
• Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

  2014cited by this paper
• Evidence for camel-to-human transmission of MERS coronavirus.

  2014cited by this paper
• Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

  2013cited by this paper
• Family cluster of Middle East respiratory syndrome coronavirus infections.

  2013cited by this paper
• Hospital outbreak of Middle East respiratory syndrome coronavirus.

  2013cited by this paper
• Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia

  2013cited by this paper
• The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies

  2013cited by this paper
• A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

  2013influential reference
• Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

  2013cited by this paper
• Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus

  2013cited by this paper
• A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV

  2013cited by this paper
• A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case

  2013cited by this paper
• A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection

  2013cited by this paper
• The history of MF59® adjuvant: a phoenix that arose from the ashes

  2013cited by this paper
• Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

  2013cited by this paper
• Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

  2012cited by this paper
• Effects of adjuvants on IgG subclasses elicited by virus-like Particles

  2012cited by this paper
• Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients

  2010cited by this paper
• Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies

  2010cited by this paper
• Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

  2010cited by this paper
• The spike protein of SARS-CoV — a target for vaccine and therapeutic development

  2009cited by this paper
• Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis.

  2008cited by this paper
• Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate

  2007cited by this paper
• Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines

  2006cited by this paper
• Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

  2005cited by this paper
• The Elderly

  1984cited by this paper
• Tetanus toxoid: what determines reaction proneness?

  1981cited by this paper
• Excessive use of tetanus toxoid boosters.

  1967cited by this paper

• Efficacy of Immunostimulatory Adjuvants and Nano‐Adjuvants in Current SARS‐CoV‐2 Vaccines: A Comprehensive Review

  2025cites this paper
• Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis

  2024cites this paper
• Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus

  2023cites this paper
• Immunogenicity of novel DNA vaccines encoding receptor‐binding domain (RBD) dimer‐Fc fusing antigens derived from different SARS‐CoV‐2 variants of concern

  2023cites this paper
• Meeting vaccine formulation challenges in an emergency setting: towards the development of accessible vaccines.

  2023cites this paper
• Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses

  2022cites this paper
• Delivery of MERS antigen encapsulated in α-GalCer-bearing liposomes elicits stronger antigen-specific immune responses

  2022cites this paper
• Reactivity and Safety of BioNTech/Pfizer® Vaccine Anti-SARS-CoV-2, in Health Personnel from the Mexican State of Guanajuato

  2022cites this paper
• Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice

  2021cites this paper
• Advances in mRNA and other vaccines against MERS-CoV

  2021cites this paper
• COVID-19 vaccine: where are we now and where should we go?

  2021cites this paper
• Efficient Human Cell Coexpression System and Its Application to the Production of Multiple Coronavirus Antigens.

  2021cites this paper
• A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development

  2021cites this paper
• SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development

  2021cites this paper
• Analysis of COVID‐19 vaccines: Types, thoughts, and application

  2021cites this paper
• Vaccine design and delivery approaches for COVID-19

  2021cites this paper
• Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections

  2021cites this paper
• A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering

  2021cites this paper
• Concept of SARS-CoV-2 Vaccine Design to Fight COVID-19 Pandemic: A Review Insight

  2021cites this paper
• The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation

  2020cites this paper
• Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

  2020cites this paper
• Vaccines against Coronaviruses: The State of the Art

  2020cites this paper
• SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen

  2020cites this paper
• Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19

  2020cites this paper
• Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development

  2020cites this paper
• An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies

  2020cites this paper
• The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies

  2020cites this paper
• Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects

  2020cites this paper
• Adjuvants for Coronavirus Vaccines

  2020cites this paper
• Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19

  2020cites this paper
• Coronavirus vaccine development: from SARS and MERS to COVID-19

  2020cites this paper
• MERS-CoV Standards, Assays and Animal Models for Vaccine Development

  2020cites this paper
• Coronavirus Infections in Children Including COVID-19 An Overview of the Epidemiology , Clinical Features , Diagnosis , Treatment and Prevention Options in Children

  2020cites this paper
• Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

  2020cites this paper
• Progress and Prospects on Vaccine Development against SARS-CoV-2

  2020cites this paper
• Coronavirus Infections in Children Including COVID-19

  2020cites this paper
• Combination of Biodata Mining and Computational Modelling in Identification and Characterization of ORF1ab Polyprotein of SARS-CoV-2 Isolated from Oronasopharynx of an Iranian Patient

  2020cites this paper
• Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains

  2020cites this paper
• The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

  2020cites this paper
• Pain Management Under COVID-19

  2020cites this paper
• Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight

  2020cites this paper
• MERS-CoV

  2019cites this paper
• Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

  2019influential citation
• Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

  2019cites this paper
• Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV

  2019cites this paper
• Antibodies and vaccines against Middle East respiratory syndrome coronavirus

  2019cites this paper
• Antibody-mediated protection against MERS-CoV in the murine model

  2019cites this paper
• MERS Coronavirus: An Emerging Zoonotic Virus

  2019cites this paper
• Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

  2019cites this paper
• A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice

  2019cites this paper
• Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

  2018cites this paper
• Prospects for a MERS-CoV spike vaccine

  2018cites this paper
• A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

  2018cites this paper
• Immunogenicity and protective ef fi cacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccines

  year unknowncites this paper